Background First-line therapy for advanced non–small-cell lung cancer (NSCLC) that lacks
targetable mutations is platinum-based chemotherapy. Among patients with a tumor …

Background Osimertinib is an oral, third-generation, irreversible epidermal growth factor
receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits both EGFR-TKI–sensitizing …

Background Most patients with locally advanced, unresectable, non–small-cell lung cancer (NSCLC)
have disease progression despite definitive chemoradiotherapy (chemotherapy …

Background An earlier analysis in this phase 3 trial showed that durvalumab significantly
prolonged progression-free survival, as compared with placebo, among patients with stage III, …

Background Osimertinib is a third-generation, irreversible tyrosine kinase inhibitor of the
epidermal growth factor receptor (EGFR-TKI) that selectively inhibits both EGFR-TKI–sensitizing …

PURPOSE The phase III PACIFIC trial compared durvalumab with placebo in patients with
unresectable, stage III non–small-cell lung cancer and no disease progression after …

… Author links open overlay panel Jhanelle E. Gray MD a , Augusto Villegas MD b , Davey …
Gray has received research funding, honoraria, and advisory fees from AstraZeneca. Dr. …

PURPOSE In KEYNOTE-189, first-line pembrolizumab plus pemetrexed-platinum significantly
improved overall survival (OS) and progression-free survival (PFS) compared with …

Epidermal growth factor receptor (EGFR) mutations typically occur in exons 18–21 and are
established driver mutations in non-small cell lung cancer (NSCLC) 1 , 2 – 3 . Targeted …

Introduction In the Phase 3, placebo-controlled PACIFIC trial of patients with unresectable,
stage III NSCLC without disease progression after concurrent chemoradiotherapy, …